Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M99.6Revenue (TTM) $M0.2Net Margin (%)-22,624.5Altman Z-Score-10.8
Enterprise Value $M67.1EPS (TTM) $-0.4Operating Margin %-20,361.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.2Pre-tax Margin (%)-22,624.5Higher ROA y-yY
Price/Book4.810-y EBITDA Growth Rate %-9.9Quick Ratio2.4Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-11.0Current Ratio2.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-75.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-215.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M166ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CYTR is held by these investors:



CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.44-77.46view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.06-73.3view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.7-79.63view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.58-78.68view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.61-78.93view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.67-79.4view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.51-78.09view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.5-78view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-89.3view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-89view

Quarterly/Annual Reports about CYTR:

News about CYTR:

Articles On GuruFocus.com
CytRx Reports Second Quarter 2017 Financial Results Aug 03 2017 
4 Biotech Stocks to Watch This Quarter Aug 01 2017 
CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumi Jul 28 2017 
CytRx Announces Reshaping of Clinical and Regulatory Executive Team Jun 13 2017 
CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas Jun 08 2017 
CytRx Reports First Quarter 2017 Financial Results May 10 2017 
CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock Apr 28 2017 
CytRx Corporation Announces Proposed Public Offering of Common Stock Apr 27 2017 
CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 Apr 21 2017 
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sar Apr 19 2017 

More From Other Websites
CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting Aug 21 2017
CytRx New Drug Development Agreement Brings Cash and Experience Aug 10 2017
CytRx reports 2Q loss Aug 04 2017
CytRx Reports Second Quarter 2017 Financial Results Aug 03 2017
4 Biotech Stocks to Watch This Quarter Aug 01 2017
Today's Research Reports on Stocks to Watch: CytRx Corporation and ImmunoGen Jul 31 2017
CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An... Jul 28 2017
Penny Stocks to Watch for June 2017 (CYTR, DELT) Jun 30 2017
CytRx Announces Reshaping of Clinical and Regulatory Executive Team Jun 13 2017
Today's Research Reports on Stocks to Watch: CytRx and Hydrogenics Corporation Jun 09 2017
CytRx Announces Update on the Regulatory Pathway for Aldoxorubicin in Soft Tissue Sarcomas Jun 08 2017
Goodbye CytRx, Your Game Is Over Jun 05 2017
Penny Stocks to Watch for June 2017 May 31 2017
Today's Research Reports on Stocks to Watch: Endocyte and CytRx May 31 2017
The Most Notable Abstracts Released Ahead Of ASCO 2017 May 19 2017
Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx May 19 2017
CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at... May 17 2017
CytRx Reports First Quarter 2017 Financial Results May 10 2017
CytRx Corporation Announces Pricing of $15 Million Public Offering of Common Stock Apr 28 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}